首页> 美国卫生研究院文献>NeuroRx >PARP Inhibition Delays Progression of Mitochondrial Encephalopathy in Mice
【2h】

PARP Inhibition Delays Progression of Mitochondrial Encephalopathy in Mice

机译:PARP抑制延缓小鼠线粒体脑病的进展。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Mitochondrial disorders are deadly childhood diseases for which therapeutic remedies are an unmet need. Given that genetic suppression of the nuclear enzyme poly (adenine diphosphate-ribose) polymerase(PARP)-1 improves mitochondrial functioning, we investigated whether pharmacological inhibition of the enzyme affords protection in a mouse model of a mitochondrial disorder. We used mice lacking the Ndufs4 subunit of the respiratory complex I (Ndufs4 knockout [ KO] mice); these mice undergo progressive encephalopathy and die around postnatal day 50. Mice were treated daily with the potent PARP inhibitor N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-(N,N-dimethylamino)acetamide hydrochloride (PJ34); neurological parameters, PARP activity, and mitochondrial homeostasis were evaluated. We found that mice receiving N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-(N,N-dimethylamino)acetamide hydrochloride from postnatal day 30 to postnatal day 50 show reduced neurological impairment, and increased exploratory activity and motor skills compared with vehicle-treated animals. However, drug treatment did not delay or reduce death. We found no evidence of increased PARP activity within the brain of KO mice compared with heterozygous, healthy controls. Conversely, a 10-day treatment with the PARP inhibitor significantly reduced basal poly(ADP-ribosyl)ation in different organs of the KO mice, including brain, skeletal muscle, liver, pancreas, and spleen. In keeping with the epigenetic role of PARP-1, its inhibition correlated with increased expression of mitochondrial respiratory complex subunits and organelle number. Remarkably, pharmacological targeting of PARP reduced astrogliosis in olfactory bulb and motor cortex, but did not affect neuronal loss of KO mice. In light of the advanced clinical development of PARP inhibitors, these data emphasize their relevance to treatment of mitochondrial respiratory defects.Electronic supplementary materialThe online version of this article (doi:10.1007/s13311-014-0285-y) contains supplementary material, which is available to authorized users.
机译:线粒体疾病是致命的儿童期疾病,治疗手段尚未得到满足。鉴于对核酶聚(腺嘌呤二磷酸核糖)聚合酶(PARP)-1的基因抑制可改善线粒体功能,我们研究了该酶的药理抑制作用是否可在线粒体疾病的小鼠模型中提供保护。我们使用的小鼠缺乏呼吸系统复合体I的Ndufs4亚基(Ndufs4基因敲除[KO]小鼠);这些小鼠会进行性脑病,并在出生后50天左右死亡。每天用强效PARP抑制剂N-(6-氧代-5,6-二氢菲啶-2-基)-(N,N-二甲基氨基)乙酰胺盐酸盐(PJ34)治疗小鼠);评估神经学参数,PARP活性和线粒体稳态。我们发现,从出生后30天到出生后50天接受N-(6-氧代-5,6-二氢菲啶-2--2-基)-(N,N-二甲基氨基)乙酰胺盐酸盐的小鼠显示出神经功能障碍的减少,并且探索活动和与经车辆处理的动物相比,运动技能。但是,药物治疗并未延迟或减少死亡。我们发现,与杂合的健康对照相比,没有证据表明KO小鼠的大脑内PARP活性增加。相反,用PARP抑制剂治疗10天可显着降低KO小鼠不同器官(包括脑,骨骼肌,肝脏,胰腺和脾脏)的基础聚(ADP-核糖基)化。与PARP-1的表观遗传学作用保持一致,其抑制作用与线粒体呼吸复合物亚基的表达增加和细胞器数目有关。值得注意的是,针对PARP的药理学靶向作用可减少嗅球和运动皮层的星形胶质变,但不会影响KO小鼠的神经元丢失。鉴于PARP抑制剂的先进临床开发,这些数据强调了它们与线粒体呼吸缺陷治疗的相关性。电子补充材料本文的在线版本(doi:10.1007 / s13311-014-0285-y)包含补充材料,可供授权用户使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号